Delta 9 Cannabis - CEO, John Arbuthnot.
CEO, John Arbuthnot.
Source: Delta 9 Cannabis.
  • Delta 9 (DN) has provided guidance and timing for its year-end 2021 results
  • It anticipates net revenue for Q4 2021 to be between C$16.6 million and $17.4 million
  • It anticipates net revenue for 2021 to be between $61.8 million and $62.6 million
  • The company will release year-end and Q4 results on March 31, 2022
  • Delta 9 Cannabis is a vertically integrated cannabis company
  • Delta 9 (DN) is up by 1.69 per cent trading at $0.30 per share

Delta 9 (DN) has provided guidance and timing for its year-end 2021 results.

It anticipates net revenue for Q4 to be between C$16.6 million and $17.4 million. This compares with $14.15 million in Q4 2020, an increase of between 17-23 per cent, and $15.2 million sequentially from Q3 2021, an increase of between 9-14 per cent.

It anticipates net revenue for 2021 to be between $61.8 million and $62.6 million, up from $52.1 million in 2021.

These numbers are unaudited.

The company will release its year-end and Q4 results on March 31, 2022, before the market opens. It has scheduled a conference call for 9:00 am EST on the same day.

“We are anticipating reporting strong year-over-year and sequential revenue results for the fourth quarter of 2021,” stated John Arbuthnot, CEO of Delta 9. “Delta 9 is working to differentiate itself from its peers by posting strong financial and operating results and continuing to grow its revenue streams from its three core business units.”

Delta 9 Cannabis is a vertically integrated cannabis company.

Delta 9 (DN) is up by 1.69 per cent trading at $0.30 per share as of 12:54 pm EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.